Vaccí contra la COVID-19: diferència entre les revisions

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=60|description=Resposta forta al domini d'unió al receptor de la [[Immunoglobulina G|IgG]] i l'[[anticòs neutralitzant]], assolint la resposta màxima als 7 dies després d'una [[dosi de reforç]], robusta pels [[limfòcits T]] CD4+ i CD8+, de durabilitat indeterminada.<ref>{{ref-notícia|cognom=Tiggle|nom=Nick|títol=Covid-19 vaccine: Allergy warning over new jab|url= https://www.bbc.co.uk/news/health-55244122 |data=9 desembre 2020|obra=BBC News|access-date=9 desembre 2020}}</ref><ref>{{ref-publicació|cognom1=Mulligan |nom1=Mark J. |cognom2=Lyke |nom2=Kirsten E. |cognom3=Kitchin |nom3=Nicholas |cognom4=Absalon |nom4=Judith |cognom5=Gurtman |nom5=Alejandra |cognom6=Lockhart |nom6=Stephen |cognom7=Neuzil |nom7=Kathleen |cognom8=Raabe |nom8=Vanessa |cognom9=Bailey |nom9=Ruth |last10=Swanson |first10=Kena A. |last11=Li |first11=Ping |last12=Koury |first12=Kenneth |last13=Kalina |first13=Warren |last14=Cooper |first14=David |last15=Fontes-Garfias |first15=Camila |last16=Shi |first16=Pei-Yong |last17=Türeci |first17=Özlem |last18=Tompkins |first18=Kristin R. |last19=Walsh |first19=Edward E. |last20=Frenck |first20=Robert |last21=Falsey |first21=Ann R. |last22=Dormitzer |first22=Philip R. |last23=Gruber |first23=William C. |last24=Şahin |first24=Uğur |last25=Jansen |first25=Kathrin U. | display-authors=6 |títol=Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults |doi-access=free |publicació=Nature |pàgines=589–593 |doi=10.1038/s41586-020-2639-4 |data= octubre 2020 |volum=586 |exemplar=7830 |pmid=32785213 |s2cid=221126922 |name-list-style=vanc }}</ref>|duration=May.{{nbsp}}2020 –}}

|{{Collapsible list|title=Emergència (21)

| [[Bahrain]]<ref>{{ref-web|títol=Bahrain becomes second country to approve Pfizer COVID-19 vaccine |url=https://www.aljazeera.com/news/2020/12/4/bahrain-becomes-second-country-to-approve-pfizer-covid-19-vaccine |website=[[Al Jazeera]] |access-date=5 desembre 2020}}</ref>

| [[Canadà]]<ref name="hcreg"/><ref name="hcapps">{{ref-web|data=9 desembre 2020|títol=Drug and vaccine authorizations for COVID-19: List of applications received|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html|consulta=9 desembre 2020|editor=Health Canada, Government of Canada}}</ref>

| [[Costa Rica]]<ref name="costa">{{ref-web|consulta=2020-12-16|títol=Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine|url=https://ticotimes.net/2020/12/16/costa-rica-authorizes-pfizer-biontech-coronavirus-vaccine|data=16 desembre 2020|website=The Tico Times}}</ref>

| [[Equador]]<ref name="ecuador">{{ref-web|títol=Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 – Agencia Nacional de Regulación, Control y Vigilancia Sanitaria|url=https://www.controlsanitario.gob.ec/arcsa-autoriza-ingreso-al-pais-de-vacuna-pfizer-biontech-para-el-covid-19/|access-date=2020-12-17|llengua=es}}</ref>

| [[Israel]]<ref>{{ref-web|títol=Israeli Health Minister ‘pleased’ as FDA approves Pfizer COVID-19 vaccine|url=https://www.jpost.com/breaking-news/fda-approves-pfizer-biontech-covid-19-vaccine-for-emergency-use-nyt-651871|access-date=2020-12-28|website=The Jerusalem Post {{!}} JPost.com|llengua=en-US}}</ref>

| [[Panamà]]<ref name="panama">{{ref-web|access-date=2020-12-16|títol=Panama approves Pfizer's COVID-19 vaccine - health ministry|url=https://finance.yahoo.com/news/panama-approves-pfizers-covid-19-010942802.html|website=finance.yahoo.com}}</ref>

| [[Qatar]]<ref>{{ref-web|access-date=2020-12-24|títol=Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-qatar/qatar-oman-to-receive-pfizer-biontech-covid-19-vaccine-this-week-idUSKBN28U0VE|website=Reuters}}</ref>

}}

{{Collapsible list|title=Plena (9)

| [[Aràbia Saudí]]<ref>{{ref-web|data=10 desembre 2020|títol=Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use|url=https://english.alarabiya.net/en/coronavirus/2020/12/10/Coronavirus-Saudi-Arabia-approves-Pfizer-COVID-19-vaccine-for-use|access-date=10 desembre 2020|website=Al Arabiya English}}</ref><ref>{{ref-notícia|cognom1=Zimmer|nom1=Carl|cognom2=Corum|nom2=Jonathan|cognom3=Wee|nom3=Sui-Lee|data=2020-06-10|títol=Coronavirus Vaccine Tracker|obra=The New York Times|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|access-date=12 desembre 2020|issn=0362-4331}}</ref>

| [[Suïssa]]<ref name="Swiss authorization">{{cite press release |title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland |url=https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html |publisher=Swiss Agency for Therapeutic Products (Swissmedic) |date=19 desembre 2020 |access-date=19 desembre 2020}}</ref>

| [[Sèrbia]]<ref>{{ref-notícia|url=https://balkaninsight.com/2020/12/21/serbia-leads-region-in-expecting-covid-19-vaccines-within-days/|obra=BalkanInsight |data=21 desembre 2020 |títol=Serbia leads region in expecting COVID-19 vaccines within days|consulta=26 desembre 2020}}</ref><ref>{{ref-notícia|url=https://www.srbija.gov.rs/vest/en/165409/first-shipment-of-pfizer-biontech-vaccine-arrives-in-serbia.php|obra=Serbian government website|data=22 desembre 2020 |títol= First shipment of Pfizer-BioNTech vaccine arrives in Serbia|consulta=26 desembre 2020}}</ref><ref>{{ref-notícia|url=https://europeanwesternbalkans.com/2020/12/24/serbia-has-started-vaccination-against-coronavirus/|obra=European Western Balkans |data=24 desembre 2020 |títol=Serbia has started vaccination against coronavirus|consulta=26 desembre 2020}}</ref>

}}

|- valign="top"

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=720|references=<ref>{{ref-publicació|cognom=National Institute of Allergy and Infectious Diseases (NIAID)|data=2020-12-03|títol=Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults|url=https://clinicaltrials.gov/ct2/show/NCT04283461|publicació= Clinial Trials|llengua=anglès|consulta= 26 desembre 2020}}</ref><ref>{{ref-web|títol=Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older |url=https://clinicaltrials.gov/ct2/show/NCT04405076|access-date=19 desembre 2020|website=ClinicalTrials.gov }}</ref>|description=Resposta d’anticossos neutralitzants dependents de la dosi segons el programa de dues dosis; durabilitat indeterminada.<ref>{{ref-publicació|cognom=Widge |nom=Alicia T. |cognom2=Rouphael |nom2=Nadine G. |cognom3=Jackson |nom3=Lisa A. |cognom4=Anderson |nom4=Evan J. |cognom5=Roberts |nom5=Paul C. |cognom6=Makhene |nom6=Mamodikoe |cognom7=Chappell |nom7=James D. |cognom8=Denison |nom8=Mark R. |cognom9=Stevens |nom9=Laura J. | last10=Pruijssers | first10=Andrea J. | last11=McDermott | first11=Adrian B. | last12=Flach | first12=Britta | last13=Lin | first13=Bob C. | last14=Doria-Rose | first14=Nicole A. | last15=O’Dell | first15=Sijy | last16=Schmidt | first16=Stephen D. | last17=Neuzil | first17=Kathleen M. | last18=Bennett | first18=Hamilton | last19=Leav | first19=Brett | last20=Makowski | first20=Mat | last21=Albert | first21=Jim | last22=Cross | first22=Kaitlyn | last23=Edara | first23=Venkata-Viswanadh | last24=Floyd | first24=Katharine | last25=Suthar | first25=Mehul S. | last26=Buchanan | first26=Wendy | last27=Luke | first27=Catherine J. | last28=Ledgerwood | first28=Julie E. | last29=Mascola | first29=John R. | last30=Graham | first30=Barney S. | last31=Beigel | first31=John H. | name-list-style=vanc | display-authors=6 |títol=Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination |publicació=New England Journal of Medicine |editorial=Massachusetts Medical Society |data=3 desembre 2020 | issn=0028-4793 | doi=10.1056/nejmc2032195 |pàgina=}}</ref><ref name="jackson">{{ref-publicació|vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |títol=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report |publicació=New England Journal of Medicine |data= juliol 2020 |volum=383 |exemplar=20 |pàgines=1920–1931 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 |pmc=7377258 |lay-url=https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ }}</ref><ref name="jackson-app">{{ref-publicació|vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |títol=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix |publicació=New England Journal of Medicine |data= juliol 2020 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 }}</ref>|locations=EUA|duration=Mar 2020{{snd}}Nov 2021}}

|{{Collapsible list|title=Emergència (4)

| [[Canadà]]<ref name="hc-moderna12-23">{{ref-web|títol=Regulatory Decision Summary - Moderna COVID-19 Vaccine - Health Canada |url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736 |editor=Health Canada, Government of Canada |access-date=23 desembre 2020 |data=23 desembre 2020}}</ref><ref name="hcapps" />

| [[Israel]]<ref name="israelmoderna">{{ref-web|títol= Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel|url=https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use|editor=modernatx.com |access-date= 4 gener 2021|data= 4 gener 2021}}</ref>

| [[Regne Unit]]<ref>{{ref-web|títol=Information for Healthcare Professionals on COVID-19 Vaccine Moderna | website=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) |data= 8 gener 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna | access-date= 8 gener 2021}}</ref><ref>{{ref-web|títol=Conditions of Authorisation for COVID-19 Vaccine Moderna | website=[[Medicines and Healthcare products Regulatory Agency]] (MHRA) |data= 8 gener 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/conditions-of-authorisation-for-covid-19-vaccine-moderna | access-date= 9 gener 2021}}</ref>

}}

{{Collapsible list|title=Plena (6)

| [[Groenlàndia]]<ref name="Danish Moderna approval" />

| [[Suïssa]]<ref>{{cite news|url=https://www.srf.ch/news/schweiz/das-neuste-zur-coronakrise-swissmedic-erteilt-zulassung-fuer-moderna-impfstoff-in-der-schweiz |title=Swissmedic erteilt Zulassung für Moderna-Impfstoff in der Schweiz |publisher=SRF |date=2020-01-12 |accessdate=2020-01-12}}</ref><ref>{{cite press release|title=Swissmedic grants authorisation for the COVID-19 vaccine from Moderna |url=https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/zulassung-covid-19-impfstoff-moderna.html |website=Swissmedic |date=2020-01-12 |accessdate=2020-01-12}}</ref>

}}

|- valign="top"

Els resultats positius d’una anàlisi provisional de quatre assaigs en curs es van anunciar el 23 de novembre de 2020 i es van publicar el 8 de desembre de 2020.<ref name="Voysey">{{ref-web| url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext |títol= Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet | format = | access-date =9 desembre 2020}}</ref> L'eficàcia general va ser del 70%, que va del 62% al 90% amb diferents règims de dosificació, amb un perfil de seguretat revisat per especialistes.<ref name = "Voysey" />|locations=Brasil (5.000),<ref>{{ref-web|títol=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |editor=[[Jenner Institute]] |access-date= 26 agost 2020 |archive-date= 9 setembre 2020 |archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch |url-status=live }}</ref> Regne Unit, Índia<ref>{{ref-notícia|títol=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |obra=mint |data= 19 agost 2020 }}</ref>|duration=maig 2020{{snd}}Aug 2021}}

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=543|description=Anticossos específics per l'espiga el dia 28; [[anticòs neutralitzant|anticossos neutralitzants]] després d'una [[dosi de reforç]] al dia 56<ref name="folegatti">{{ref-publicació|cognom1=Folegatti |nom1=Pedro M |cognom2=Ewer |nom2=Katie J |cognom3=Aley |nom3=Parvinder K |cognom4=Angus |nom4=Brian |cognom5=Becker |nom5=Stephan |cognom6=Belij-Rammerstorfer |nom6=Sandra |cognom7=Bellamy |nom7=Duncan |cognom8=Bibi |nom8=Sagida |cognom9=Bittaye |nom9=Mustapha |last10=Clutterbuck |first10=Elizabeth A |last11=Dold |first11=Christina |last12=Faust |first12=Saul N |last13=Finn |first13=Adam |last14=Flaxman |first14=Amy L |last15=Hallis |first15=Bassam |last16=Heath |first16=Paul |last17=Jenkin |first17=Daniel |last18=Lazarus |first18=Rajeka |last19=Makinson |first19=Rebecca |last20=Minassian |first20=Angela M |last21=Pollock |first21=Katrina M |last22=Ramasamy |first22=Maheshi |last23=Robinson |first23=Hannah |last24=Snape |first24=Matthew |last25=Tarrant |first25=Richard |last26=Voysey |first26=Merryn |last27=Green |first27=Catherine |last28=Douglas |first28=Alexander D |last29=Hill |first29=Adrian V S |last30=Lambe |first30=Teresa |last31=Gilbert |first31=Sarah C |last32=Pollard |first32=Andrew J |display-authors=6 |author-link2=Katie Ewer |títol=Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial |publicació=Lancet |data= juliol 2020 |volum=396 |exemplar=10249 |pàgines=467–78 |doi=10.1016/S0140-6736(20)31604-4 |pmid=32702298 |pmc=7445431 |doi-access=free |lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-oxford-az-vaccine |name-list-style=vanc }}</ref>}}

| [[Argentina]]<ref>{{ref-web|títol=Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine |url=https://www.reuters.com/article/us-health-coronavirus-argentina-astrazen/argentine-regulator-approves-astrazeneca-oxford-covid-19-vaccine-astrazeneca-idUSKBN29421P |website=reuters.com |editor=

Reuters |access-date=30 desembre 2020 |data=30 desembre 2020}}</ref>

| [[República Dominicana]]<ref>{{ref-notícia|cognom1=Staff |nom1=Agencia EFE |títol=La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19 |url=https://www.efe.com/efe/america/sociedad/la-republica-dominicana-aprueba-vacuna-de-astrazeneca-contra-covid-19/20000013-4431079 |obra=Agencia EFE |data=31 desembre 2020 |llengua=es}}</ref>

| [[Mèxic]]<ref>{{ref-web|cognom=Sanitarios|nom=Comisión Federal para la Protección contra Riesgos|títol=AUTORIZACIÓN PARA USO DE EMERGENCIA A VACUNA ASTRAZENECA COVID-19|url=http://www.gob.mx/cofepris/articulos/autorizacion-para-uso-de-emergencia-a-vacuna-astrazeneca-covid-19?idiom=es|access-date=2021-01-05|website=gob.mx|llengua=es}}</ref>

}}

{{Collapsible list|title=Plena (0)

|{{ClinicalStudyInfo|align=left|phase=3|participants=40000|description=Doble cec aleatoritzat, controlat amb placebo per avaluar l'eficàcia, la immunogenicitat i la seguretat<ref>{{ref-web|títol=Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |website=ClinicalTrials.gov |access-date= 11 setembre 2020 |archive-date= 12 setembre 2020 |archive-url=https://web.archive.org/web/20200912231654/https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |url-status=live }}</ref>|locations=Rússia, Índia<ref>{{ref-notícia|cognom1=Kumar |nom1=Shivani |títol=Sputnik-V from Russia arrives in India for clinal trials |url=https://www.hindustantimes.com/india-news/sputnik-v-from-russia-arrives-in-india-for-clinal-trials/story-b8k3Ecncxw2RBTrIxOiqxO.html |obra=Hindustan Times |data=1 desembre 2020 }}</ref><ref>{{ref-notícia|títol=Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune |url=https://indianexpress.com/article/india/clinical-trial-17-volunteers-given-russias-sputnik-v-covid-19-vaccine-in-pune-7094153/ |obra=The Indian Express |data=6 desembre 2020 }}</ref>|duration=Ago 2020 - Mai 2021}}

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=76|description=Respostes dels [[anticossos neutralitzants]] i [[limfòcits T]].<ref name="logunov">{{ref-publicació|cognom1=Logunov |nom1=Denis Y |cognom2=Dolzhikova |nom2=Inna V |cognom3=others |títol=Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia |publicació=The Lancet |any=2020 |volum=396 |exemplar=10255 |pàgines=887–97 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31866-3 | pmid=32896291 | pmc=7471804 | s2cid=221472251 | doi-access=free | name-list-style=vanc }}</ref>|locations=Rússia|duration=Jun 2020<ref name="logunov" /> - Set 2020}}

| [[Argentina]]<ref>[https://sputnikvaccine.com/newsroom/pressreleases/argentina-has-registered-the-sputnik-v-vaccine-based-on-russian-clinical-trial-data-/ ''Sputnik Vaccine Newsroom'']. 23 December 2020.</ref>>

| [[Bolívia]]<ref>{{ref-notícia|títol=Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19 |url=https://www.minsalud.gob.bo/5114-bolivia-y-rusia-firman-contrato-para-adquirir-5-2-millones-de-dosis-de-la-vacuna-sputnik-v-contra-el-covid-19 |access-date= 1 gener 2021 |obra=www.minsalud.gob.bo}}</ref>

| [[Guinea]]<ref>{{ref-notícia|títol=Guinea Begins Administering Russia's Sputnik V Covid-19 Vaccine |url=https://www.africanews.com/2020/12/31/guinea-begins-administering-russia-s-sputnik-v-covid-19-vaccine/ |obra=africanews. |data=31 desembre 2020 |llengua=en}}</ref>

| [[Palestina]]<ref>{{cite news |title=Palestine has become the first country in the Middle East to register Sputnik V vaccine |url=https://rdif.ru/Eng_fullNews/6279/ |work=RFID |date=11 January 2021 |language=en}}</ref>

}}

{{Collapsible list|title=Plena (0)

|{{ClinicalStudyInfo|align=left|phase=2|participants=600|description=Immunogenicitat que provoca un 92% de seroconversió a dosis més baixes i un 98% a dosis més altes després de 14 dies<ref>{{ref-publicació|cognom1=Zhang |nom1=Yanjun |cognom2=Zeng |nom2=Gang |cognom3=Pan |nom3=Hongxing |cognom4=Li |nom4=Changgui |cognom5=Hu |nom5=Yaling |cognom6=Chu |nom6=Kai |cognom7=Han |nom7=Weixiao |cognom8=Chen |nom8=Zhen |cognom9=Tang |nom9=Rong |last10=Yin |first10=Weidong |last11=Chen |first11=Xin |last12=Hu |first12=Yuansheng |last13=Liu |first13=Xiaoyong |last14=Jiang |first14=Congbing |last15=Li |first15=Jingxin |last16=Yang |first16=Minnan |last17=Song |first17=Yan |last18=Wang |first18=Xiangxi |last19=Gao |first19=Qiang |last20=Zhu |first20=Fengcai | display-authors=6 |títol=Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial |publicació=The Lancet Infectious Diseases |data= novembre 2020 |volum=0 |doi=10.1016/S1473-3099(20)30843-4 |pmid=33217362 |s2cid=227099817 | doi-access=free |name-list-style=vanc }}</ref>|locations=Xina|duration=Mai 2020 -}}

|{{Collapsible list|title=Emergència (4)

| [[Bolívia]]<ref>{{ref-web|títol=Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19 |url=https://noticias.uol.com.br/internacional/ultimas-noticias/2021/01/06/bolivia-autoriza-uso-de-vacinas-sputnik-v-e-coronavac-contra-covid-19.htm |website=noticias.uol.com.br |access-date= 6 gener 2021 |llengua=pt-br}}</ref>

| [[Indonèsia]]<ref name=StraitsTimes20210111>{{cite news |url=https://www.straitstimes.com/asia/se-asia/indonesia-grants-emergency-use-approval-to-sinovac-vaccine-local-trials-show-65 |title=Indonesia grants emergency use approval to Sinovac’s vaccine, local trials show 65% efficacy |last=Soeriaatmadja |first=Wahyudi |work=The Straits Times |date=2021-01-11 |accessdate=2021-01-11}}</ref><ref name=Tempo>{{cite news |title=BPOM Grants Emergency Use Authorization for Sinovac Vaccine |url=https://en.tempo.co/read/1422220/bpom-grants-emergency-use-authorization-for-sinovac-vaccine |work=[[Tempo (Indonesian magazine)|Tempo]] |date=2021-01-11 |accessdate=2021-01-11}}</ref>

| [[Turquia]]<ref>{{cite news |title=Turkey to begin COVID-19 vaccine jabs by this weekend |url=https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/turkey-to-begin-covid-19-vaccine-jabs-by-this-weekend/2106366 |work=Anadolu |date=2021-01-11 |accessdate=2021-01-11}}</ref>

}}

{{Collapsible list|title=Plena (0)

}}

{{Collapsible list|title=Plena (3)

| [[Bahrain]]

| [[Xina]]

}}